CMT Treatment Report

www.CMTTreatmentReport.com

ACE-083

Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Charcot-Marie Tooth (CMT) Disease Type 1 (CMT1) and Type X (CMTX) [Terminated]

https://clinicaltrials.gov/ct2/show/NCT03943290?type=Intr&cond=Charcot-Marie-Tooth&lupd_s=04%2F25%2F2019&lupd_d=14

Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)

Conditions :   Facioscapulohumeral Muscular Dystrophy;   Charcot-Marie-Tooth Disease

Intervention :   Drug: ACE-083

Sponsor :   Acceleron Pharma, Inc.

Recruiting

NCT03943290

Thu, 09 May 2019 12:00:00 EDT

Acceleron Abandons Charcot-Marie-Tooth Program (ACE-083) After Phase II Trial Failure

https://www.biospace.com/article/acceleron-s-ace-083-flunks-charcot-marie-tooth-disease-trial/

Acceleron Abandons Charcot-Marie-Tooth Program After Trial Failure

Cambridge, Massachusetts-based Acceleron Pharma announced that its Phase II clinical trial of ACE-083 in patients with Charcot-Marie-Tooth disease (CMT) failed to show functional improvement

Acceleron Pharma Initiates Phase 2 Clinical Trial to Evaluate Long-Term Effects of ACE-083 in Patients with Charcot-Marie Tooth (CMT) Disease

This new ACE-083 study was added to ClinicalTrials.gov on May 9, 2019 and is now enrolling patients with CMT1 and CMTX across the United States, Canada, and Spain.

The FDA granted Fast Track designation to ACE-083, Acceleron Pharma’s “locally-acting ‘Myostatin+’ muscle agent” for the treatment of Charcot-Marie-Tooth disease (CMT), back in November 2018. See this press release for full background story.

Acceleron Pharma continues to move ACE-083 forward, as planned, with this newest study.

STUDY LINK: https://clinicaltrials.gov/ct2/show/study/NCT03943290

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

https://clinicaltrials.gov/ct2/show/NCT03124459?type=Intr&cond=Charcot-Marie-Tooth&lupd_s=10%2F30%2F2018&lupd_d=14

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

Condition :   Charcot-Marie-Tooth Disease

Interventions :   Drug: ACE-083;   Drug: Placebo

Sponsor :   Acceleron Pharma, Inc.

Recruiting

NCT03124459

Fri, 21 Apr 2017 12:00:00 EDT

  • added more locations
  • dec 5, 2018 updated
  • jan 15, 2019 updated (vermont study location added)

Acceleron Receives FDA Fast Track Designation for ACE-083 in Charcot-Marie-Tooth Disease

https://www.businesswire.com/news/home/20181128005059/en/Acceleron-Receives-FDA-Fast-Track-Designation-ACE-083

Acceleron Receives FDA Fast Track Designation for ACE-083 in Charcot-Marie-Tooth Disease

>>> nov 28, 2018 / press release

http://investor.acceleronpharma.com/news-releases/news-release-details/acceleron-receives-fda-fast-track-designation-ace-083-charcot

 

Back to top